Blood matrix metalloproteinase 9 (MMP-9) level is a promising new diagnostic marker. The aim of the current case—control study is to investigate the correlation between the serum MMP-9 level with occurrence and progression of breast cancer. The serum MMP-9 level was investigated by gelatin zymography in 100 patients with breast cancer and 120 healthy participants. The average value of MMP-9 activity was significantly higher in patients with breast cancer than in control ( P < .002), this value correlates with tumor stage ( P = .005) and tumor size ( P = .012). Our results suggest serum MMP-9 level is a potential diagnostic marker for predicting breast cancer occurrence and progression.
la-aho R., Kahari VMCollagenases in cancer. Biochimie. 2005; 87(3-4):273-286.
3.
Stamenkovic I.Matrix metalloproteinases in tumor invasion and metastasis. Semin Cancer Biol. 2000;10(6):415-433.
4.
Egeblad M., Werb Z.New functions for the matrix metalloproteinases in cancer progression. Nat Rev Cancer. 2002;2(3): 161-174.
5.
Kahari VM, Saarialho-Kere U.Matrix metalloproteinases and their inhibitors in tumour growth and invasion . Ann Med. 1999;31(1):34-45.
6.
Zucker S., Hymowitz M., Conner C., et al. Measurement of matrix metalloproteinases and tissue inhibitors of metalloproteinases in blood and tissues. Clin Exp Appl . 1999;878: 212-227.
7.
Rocca G., La Pucci-Minafra I., Marrazzo V., Taormina V., Minafra V.Zymographic detection and clinical correlations of MMP-2 and MMP-9 in breast cancer sera. Br J Cancer. 2004;90:1414-1421.
8.
Chun-Ying W. , Ming-Shiang W., En-Pei C., et al. Plasma matrix metalloproteinase-9 level is better than serum matrix metalloproteinase-9 level to predict gastric cancer evolution. Clin Cancer Res. 2007;13(7):2054-2060.
9.
Hoikkala S., Paakko P., Soini Y., Makitaro R., Kinnula V., Turpeenniemi-Hujanen T.Tissue MMP-2/TIMP-2-complex are better prognostic factors than serum MMP-2, MMP-9 or TIMP-1 in stage I-III lung carcinoma. Cancer Lett . 2005; 236(1):125-132.
10.
Ruokolainen H., Paakko P., Turpeenniemi-Hujanen T.Serum matrix metalloproteinase-9 in head and neck squamous cell carcinoma is a prognostic marker. Int J Cancer. 2005;116(3): 422-427.
11.
Hayasaka A. , Suzuki N., Fujimoto N., et al. Elevated plasma levels of matrix metalloproteinase-9 (92-kd type IV collagenase/gelatinase B) in hepatocellular carcinoma. Hepatology. 1996;24(5):1058-1062.
12.
Leeman MF, Curran S., Murray GINew insights into the roles of matrix metalloproteinases in colorectal cancer development and progression. J Pathol. 2003 ;201(4):528-534.
13.
Barbara S., Dieter P., Kathrin H., et al. Increased expression of matrix metalloproteinases (MMP)-2, MMP-9, and the urokinase-type plasminogen activator is associated with progression from benign to advanced ovarian cancer. Clin Cancer Res. 2001;7(8):2396-2404.
14.
Duffy MJ, Maguire TM, Hill A., McDermott E., O’Higgins N.Metalloproteinases: role in breast carcinogenesis, invasion and metastasis . Breast Cancer Res. 2000;2(4):252-257.
15.
Leeman MF, Curran S., Murray GINew insights into the roles of matrix metalloproteinases in colorectal cancer development and progression. J Pathol. 2003 ;201(4):528-534.
16.
Ranuncolo SM , Armanasco E., Cresta C., Bal De Kier Joffe E., Puricelli L.Plasma MMP-9 (92 kDa-MMP) activity is useful in the follow-up and in the assessment of prognosis in breast cancer patients. Int J Cancer. 2003;106(5):745-751.
17.
Fernandez-Patron C., Martinez-Cuesta MA, Salas E., et al. Differential regulation of platelet aggregation by matrix metalloproteinases-9 and -2. Thromb Haemost. 1999;82(6): 1730-1735.
18.
Mannello F.Effects of blood collection methods on gelatin zymography of matrix metalloproteinases. Clin Chem. 2003; 49(2):339-340.
19.
Makowski GS , Ramsby MLCalibrating gelatin zymograms with human gelatinase standards. Anal Biochem. 1996;236(2): 353-356.
van’t Veer LJ, Dai H., van de, et al. Gene expression profiling predicts clinical outcome of breast cancer. Nature. 2002;415(6871):530-535.
22.
King J., Zhao J., Clingan P., Morris D.Randomised double blind placebo control study of adjuvant treatment with the metalloproteinase inhibitor, Marimastat in patients with inoperable colorectal hepatic metastases: significant survival advantage in patients with musculoskeletal side-effects. Anticancer Res. 2003;23(1B):639-645.
23.
Garbisa S., Scagliotti G., Masiero L., et al. Correlation of serum metalloproteinase levels with lung cancer metastasis and response to therapy. Cancer Res. 1992;52(16):4548-4549.
24.
Zucker S., Lysik RM, Zarrabi MH, Moll U.M(r) 92 000 type IV collagenase is increased in plasma of patients with colon cancer and breast cancer. Cancer Res. 1993 ;53(1): 140-146.
25.
Hayasaka A. , Suzuki N., Fujimoto N., et al. Elevated plasma levels of matrix metalloproteinase-9 92-kD type IV collagenasegelatinase B in hepatocellular carcinoma. Hepatology. 1996; 24(5):1058-1062.
26.
Endo K., Maehara Y., Baba H., et al. Elevated levels of serum and plasma metalloproteinases in patients with gastric cancer. Anticancer Res. 1997;17(3C):2253-2258.
27.
Yang SF, Hsieh YS, Lin CL, et al. Increased plasma levels of urokinase plasminogen activator and matrix metalloproteinase-9 in nonsmall cell lung cancer patients. Clin Chim Acta. 2005; 354(1-2):91-99.
28.
Decock J., Hendrickx W., Wildiers H., et al. Plasma gelatinase levels in patients with primary breast cancer in relation to axillary lymph node status, Her2/neu expression and other clinicopathological variables. Clin Exp Metastasis. 2005;22(6): 495-502.
29.
Somiari SB, Shriver CD, Heckman C., et al. Plasma concentration and activity of matrix metalloproteinase 2 and 9 in patients with breast disease, breast cancer and at high risk of developing breast cancer. Cancer Lett. 2006 ;233(1):98-107.
30.
Nikkola J., Vihinen P., Vuoristo MS, Kellokumpu-Lehtinen P., Kahari VM, Pyrhonen S.High serum levels of matrix metalloproteinase-9 and matrix metalloproteinase-1 are associated with rapid progression in patients with metastatic melanoma . Clin Cancer Res. 2005;11(14):5158-5166.
31.
Hanemaaijer R., Verheijen JH, Maguire TM, et al. Increased gelatinase-A and gelatinase-B activities in malignant vs. benign breast tumors. Int J Cancer . 2000;86(2):204-207.
